Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
The Crushed Pile in Nevada: How a Forgotten 1989 Gold Heap Is Becoming One of America's Few Near-Term Antimony Solutions
